Sarepta Therapeutics (SRPT) +8% to $29.16 after Piper Jaffray says the biotech has the potential...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Sarepta Therapeutics (SRPT) +8% to $29.16 after Piper Jaffray says the biotech has the potential to be a $160/share stock, although its nearer-term range could be $60-$80. Efsinvestment's Ahmed Ishtiaq wrote on Seeking Alpha this week that Sarepta is "ready to move higher." The company's lead drug is Eteplirsen for the treatment of Duchenne muscular dystrophy, which looks like it could be a blockbuster.